Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK8 and CDK19. It is investigated for its potential in treating cancers by modulating transcriptional regulation and interfering with oncogenic signaling pathways. Shows activity in models of acute myeloid leukemia (AML) and other hematological malignancies by inducing apoptosis and reducing tumor cell proliferation. Also serves as a chemical probe to study the role of CDK8 in gene expression and immune response. Its selectivity makes it valuable for understanding the therapeutic potential of targeting specific CDK complexes without broad inhibition of cell cycle CDKs.